Cerebral Stroke, Malondialdehyde, Oxidative Stress
Conditions
Keywords
Astaxanthin, Antioxidant, Plasma Malondialdehyde, NIHSS score, Ischemic Stroke
Brief summary
This is an interventional randomized, controlled trial in analyzing the effects of astaxanthin supplementation on plasma malondialdehyde levels and NIHSS of acute ischemic stroke patients. According to published studies, it was hypothesized that acute ischemic stroke patients who were given astaxanthin would have lower plasma malondialdehyde levels and lower NIHSS score compared to the control group.
Detailed description
There were a total of 24 subjects, with 12 subjects in the intervention group and 12 subjects in the control group.The participants were divided into an interventional group and a control group. The interventional group was given astaxanthin supplementation 2 x 8mg per day for 7 days, while the control group was given placebo.
Interventions
DRUGAstaxanthine
DRUGPlacebo Oral Tablet
Sponsors
Indonesia University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Intervention model description
Astaxanthin and Placebo
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 40-65 years old * Has acute ischemic stroke with an onset of less than 48 hours before hospital admission * NIHSS score of less than or equal to 15 * Can consume food orally or enterally * Has given their consent to be a participant in the study
Exclusion criteria
* Renal failure * Liver failure * Is taking supplements other than his or her main stroke medications * Has taken antioxidant supplements in the last 3 months before stroke onset
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma Malondialdehyde Levels on Astaxanthine Treated Stroke Patients as Assessed by Wills Spectrophotometry | 7 days | This method used Thiobarbituric acid reaction (TBAR) with substances such as malondialdehyde. The scale was 0.367 nmol/ml-0.707 nmol/ml. The value above 0.707nmol/ml would be the worse outcome, and value less than 0.367nmol/ml would be the best outcome. Bivariate analysis was used to analyze the results (T-test or the Mann-Whitney Test). |
| National Institute of Health Stroke Scale on Astaxanthine Treated Stroke Patients | 7 days | Score scale was 4-15, where less than 4 indicates mild neurologic deficit, 4-15 moderate neurologic deficit, and more than 15 severe neurologic deficit. They will be assessed before and after the trial to compare how each participant improved after given the intervention. |
Countries
Indonesia
Outcome results
None listed